7.21  -0.04 (-0.55%)		10-24 15:00
Open: 7.29 High: 7.4194 Volume: 62,963		Pre. Close: 7.25 Low: 7.2 Market Cap: 150(M)

Short term
Mid term
Targets	6-month :	9.03	1-year :	9.91
Resists	First :	7.73	Second :	8.48
Pivot price	7.51
Supports	First :	6.52	Second :	5.42
MAs	MA(5) :	7.28	MA(20) :	7.33
	MA(100) :	7.36	MA(250) :	8.03
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	27.4	D(3) :	30.9
RSI	RSI(14): 47.3
52-week	High :	11.98	Low :	5.46

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ACTU ] has closed above bottom band by 33.3%. Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	7.41 - 7.46	7.46 - 7.5
Low:	6.98 - 7.04	7.04 - 7.1
Close:	7.15 - 7.25	7.25 - 7.34

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Mon, 22 Sep 2025
Actuate Therapeutics Reports Positive Progress on Elraglusib as Backbone Therapy for Pancreatic Cancer Amid Ongoing Clinical Trials and Financing Milestone - Quiver Quantitative

Mon, 22 Sep 2025
Actuate reports positive survival data for pancreatic cancer drug - Investing.com

Thu, 11 Sep 2025
Actuate Therapeutics Announces Closing of $17.25 Million - GlobeNewswire

Wed, 10 Sep 2025
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - GlobeNewswire

Tue, 09 Sep 2025
Actuate Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire

Tue, 09 Sep 2025
Actuate Therapeutics announces public offering of common stock - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	23 (M)
Shares Float	11 (M)
Held by Insiders	16.1 (%)
Held by Institutions	48.9 (%)
Shares Short	615 (K)
Shares Short P.Month	549 (K)

EPS	-3.11
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.13
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-349 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-23 (M)
Levered Free Cash Flow	-15 (M)

PE Ratio	-2.34
PEG Ratio	0
Price to Book value	-55.77
Price to Sales	0
Price to Cash Flow	-7.42

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.